The associations of particular serum blood biomarkers used in routine clinical practice with treatment response and PFS of patients with advanced NSCLC on anti‐PD‐1 therapy were investigated, with the aim of identifying available biomarkers that could aid in predicting treatment responses or PFS with clinical applicability. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.